vs
BillionToOne, Inc.（BLLN）与Guardant Health, Inc.（GH）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是BillionToOne, Inc.的3.4倍（$281.3M vs $83.5M）。BillionToOne, Inc.净利率更高（6.8% vs -45.7%，领先52.5%）。BillionToOne, Inc.同比增速更快（117.4% vs 39.4%）。BillionToOne, Inc.自由现金流更多（$6.5M vs $-54.2M）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
BLLN vs GH — 直观对比
营收规模更大
GH
是对方的3.4倍
$83.5M
营收增速更快
BLLN
高出78.0%
39.4%
净利率更高
BLLN
高出52.5%
-45.7%
自由现金流更多
BLLN
多$60.7M
$-54.2M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $281.3M |
| 净利润 | $5.7M | $-128.5M |
| 毛利率 | 69.9% | 64.6% |
| 营业利润率 | 11.5% | -43.0% |
| 净利率 | 6.8% | -45.7% |
| 营收同比 | 117.4% | 39.4% |
| 净利润同比 | 138.3% | -15.8% |
| 每股收益（稀释后） | $0.10 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNGH
| Q4 25 | — | $281.3M | ||
| Q3 25 | $83.5M | $265.2M | ||
| Q2 25 | — | $232.1M | ||
| Q1 25 | — | $203.5M | ||
| Q4 24 | — | $201.8M | ||
| Q3 24 | $38.4M | $191.5M | ||
| Q2 24 | — | $177.2M | ||
| Q1 24 | — | $168.5M |
净利润BLLNGH
| Q4 25 | — | $-128.5M | ||
| Q3 25 | $5.7M | $-92.7M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | — | $-95.2M | ||
| Q4 24 | — | $-111.0M | ||
| Q3 24 | $-14.9M | $-107.8M | ||
| Q2 24 | — | $-102.6M | ||
| Q1 24 | — | $-115.0M |
毛利率BLLNGH
| Q4 25 | — | 64.6% | ||
| Q3 25 | 69.9% | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | 52.6% | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
营业利润率BLLNGH
| Q4 25 | — | -43.0% | ||
| Q3 25 | 11.5% | -37.3% | ||
| Q2 25 | — | -45.9% | ||
| Q1 25 | — | -54.6% | ||
| Q4 24 | — | -62.4% | ||
| Q3 24 | -32.9% | -61.3% | ||
| Q2 24 | — | -56.8% | ||
| Q1 24 | — | -59.2% |
净利率BLLNGH
| Q4 25 | — | -45.7% | ||
| Q3 25 | 6.8% | -35.0% | ||
| Q2 25 | — | -43.0% | ||
| Q1 25 | — | -46.8% | ||
| Q4 24 | — | -55.0% | ||
| Q3 24 | -38.8% | -56.3% | ||
| Q2 24 | — | -57.9% | ||
| Q1 24 | — | -68.2% |
每股收益（稀释后）BLLNGH
| Q4 25 | — | $-1.01 | ||
| Q3 25 | $0.10 | $-0.74 | ||
| Q2 25 | — | $-0.80 | ||
| Q1 25 | — | $-0.77 | ||
| Q4 24 | — | $-0.90 | ||
| Q3 24 | $-1.47 | $-0.88 | ||
| Q2 24 | — | $-0.84 | ||
| Q1 24 | — | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | $378.2M |
| 总债务越低越好 | $55.0M | $1.5B |
| 股东权益账面价值 | $-239.5M | $-99.3M |
| 总资产 | $327.5M | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLLNGH
| Q4 25 | — | $378.2M | ||
| Q3 25 | $195.2M | $580.0M | ||
| Q2 25 | — | $629.1M | ||
| Q1 25 | — | $698.6M | ||
| Q4 24 | — | $525.5M | ||
| Q3 24 | — | $585.0M | ||
| Q2 24 | — | $933.7M | ||
| Q1 24 | — | $1.0B |
总债务BLLNGH
| Q4 25 | — | $1.5B | ||
| Q3 25 | $55.0M | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BLLNGH
| Q4 25 | — | $-99.3M | ||
| Q3 25 | $-239.5M | $-354.5M | ||
| Q2 25 | — | $-305.5M | ||
| Q1 25 | — | $-250.8M | ||
| Q4 24 | — | $-139.6M | ||
| Q3 24 | $-242.9M | $-60.1M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $68.3M |
总资产BLLNGH
| Q4 25 | — | $2.0B | ||
| Q3 25 | $327.5M | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | $-54.2M |
| 自由现金流率自由现金流/营收 | 7.7% | -19.3% |
| 资本支出强度资本支出/营收 | 8.8% | 9.9% |
| 现金转化率经营现金流/净利润 | 2.42× | — |
| 过去12个月自由现金流最近4个季度 | — | $-233.1M |
8季度趋势，按日历期对齐
经营现金流BLLNGH
| Q4 25 | — | $-26.4M | ||
| Q3 25 | $13.8M | $-35.4M | ||
| Q2 25 | — | $-60.3M | ||
| Q1 25 | — | $-62.7M | ||
| Q4 24 | — | $-64.5M | ||
| Q3 24 | — | $-51.1M | ||
| Q2 24 | — | $-94.0M | ||
| Q1 24 | — | $-30.3M |
自由现金流BLLNGH
| Q4 25 | — | $-54.2M | ||
| Q3 25 | $6.5M | $-45.8M | ||
| Q2 25 | — | $-65.9M | ||
| Q1 25 | — | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | — | $-55.3M | ||
| Q2 24 | — | $-99.1M | ||
| Q1 24 | — | $-37.2M |
自由现金流率BLLNGH
| Q4 25 | — | -19.3% | ||
| Q3 25 | 7.7% | -17.3% | ||
| Q2 25 | — | -28.4% | ||
| Q1 25 | — | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | — | -28.9% | ||
| Q2 24 | — | -55.9% | ||
| Q1 24 | — | -22.1% |
资本支出强度BLLNGH
| Q4 25 | — | 9.9% | ||
| Q3 25 | 8.8% | 3.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | 4.1% |
现金转化率BLLNGH
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
